A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
AIMS: Finerenone (BAY 94-8862) is a novel non-steroidal mineralocorticoid receptor antagonist. The aim of this study was to compare the efficacy and safety of seven once-daily oral doses of finerenone (1.25-20mg) and placebo in 96 patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN) receiving a RAS blocker. METHODS: ARTS-DN Japan was a multicenter, randomized, double-blind, placebo-controlled, phase 2b study. RESULTS: Analysis of the urinary albumin-to-creatinine ratio (UACR) at day 90 relative to baseline indicated a nominally significant effect of finerenone. The UACR at day 90 relative to baseline for each finerenone treatment group was numerically reduced compared with placebo. No serious adverse events (AEs) or deaths were reported and no patients experienced treatment-emergent AEs resulting in discontinuation of study drug. Small mean increases in serum potassium level were observed in the finerenone treatment groups (0.025-0.167mmol/L) compared with the placebo group (-0.075mmol/L); no patients developed hyperkalemia. CONCLUSION: When given in addition to a RAS inhibitor, finerenone reduced albuminuria without adverse effects on serum potassium levels or renal function in Japanese patients with T2DM and DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Self-citationEffectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000091 · Cited by 430
Self-citationRise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., & for the INNOVATION Study Group (2007) · Diabetes Care · doi:10.2337/dc06-1998 · Cited by 230
Self-citationPrediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164
Evidence-based practice guideline for the treatment for diabetes in Japan 2013
Tajima, N., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Fujimoto, K., Sakamoto, M., & Haneda, M. (2015) · Diabetology International · doi:10.1007/s13340-015-0206-2 · Cited by 154
Cited by
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Naaman, S. C., & Bakris, G. L. (2023) · Diabetes Care · doi:10.2337/dci23-0030 · Cited by 292
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157
Chaudhuri, A., Ghanim, H., & Arora, P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14601 · Cited by 120
“Similar findings were observed in the ARTS-DN Japan study.(81) ARTS-HF showed that finerenone and eplerenone induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients who presented in emergency departments with worsening chronic HF with reduced LVEF.”
ResultWada, T., Inagaki, M., Yoshinari, T., Terata, R., Totsuka, N., Gotou, M., & Hashimoto, G. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01963-z · Cited by 97
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Metadata
- Authors
- Katayama, S., Yamada, D., Nakayama, M., Yamada, T., Myoishi, M., Kato, M., Nowack, C., Kolkhof, P., & Yamasaki, Y.
- Venue
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 31
- Issue
- 4
- Pages
- 758-765
- ISSN
- 0891-6632 (ISSN-L)
- 1056-8727
- OpenAlex
- W2562375370
- Cited by
- 132
- References
- 9
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.